ARTICLE

Received 23 Dec 2014 | Accepted 10 Feb 2015 | Published 31 Mar 2015

DOI: 10.1038/ncomms7651

OPEN

Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss

Ulrike Harre¹, Stefanie C. Lang¹, René Pfeifle^{1,2}, Yoann Rombouts^{3,4}, Sabine Frühbeißer⁵, Khaled Amara⁶, Holger Bang⁷, Anja Lux⁸, Carolien A. Koeleman^{3,4}, Wolfgang Baum¹, Katharina Dietel¹, Franziska Gröhn⁵, Vivianne Malmström⁶, Lars Klareskog⁶, Gerhard Krönke^{1,2}, Roland Kocijan¹, Falk Nimmerjahn⁸, René EM Toes³, Martin Herrmann¹, Hans Ulrich Scherer³ & Georg Schett¹

Immunoglobulin G (IgG) sialylation represents a key checkpoint that determines the engagement of pro- or anti-inflammatory Fcγ receptors (FcγR) and the direction of the immune response. Whether IgG sialylation influences osteoclast differentiation and subsequently bone architecture has not been determined yet, but may represent an important link between immune activation and bone loss. Here we demonstrate that desialylated, but not sialylated, immune complexes enhance osteoclastogenesis *in vitro* and *in vivo*. Furthermore, we find that the Fc sialylation state of random IgG and specific IgG autoantibodies determines bone architecture in patients with rheumatoid arthritis. In accordance with these findings, mice treated with the sialic acid precursor N-acetylmannosamine (ManNAc), which results in increased IgG sialylation, are less susceptible to inflammatory bone loss. Taken together, our findings provide a novel mechanism by which immune responses influence the human skeleton and an innovative treatment approach to inhibit immune-mediated bone loss.

¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen 91054, Germany. ²Nikolaus Fiebiger Center of Molecular Medicine, University of Erlangen-Nuremberg, Erlangen 91054, Germany. ³Department of Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands. ⁴Center of Proteomics and Metabolomics, Leiden University Medical Center, Leiden 2300 RC, The Netherlands. ⁵Department of Chemistry and Pharmacy, Interdisciplinary Center for Molecular Materials (ICMM), University of Erlangen-Nuremberg, Erlangen 91054, Germany. ⁶Rheumatology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Solna 17177, Sweden. ⁷Orgentec Diagnostika, Mainz 55129, Germany. ⁸Department of Genetics, University of Erlangen-Nuremberg, Erlangen 91054, Germany. Correspondence and requests for materials should be addressed to G.S. (email: georg.schett@uk-erlangen.de).

IgG is a potent effector protein of the humoral immune response. Besides its role in antigen binding, IgG has been well established to regulate the activity of immune cells by binding to activating or inhibitory FcγR, mediating key effector functions of IgG such as the clearance of pathogens or antibody-dependent cellular cytotoxicity. The binding of IgG to FcγR is influenced by the glycan attached to asparagine-297 in the Fc part of IgG¹. This glycan is composed of a conserved heptamer backbone that consists of N-acetylglucosamine and mannose residues and is modified by the addition of several sugar moieties (Supplementary Fig. 1). Changes in IgG glycosylation are considered to result in an altered Fc conformation and affect the binding affinity of IgG to FcγR^{2,3}. Hence, attachment of terminal sialic acid residues on IgG appears to mediate the anti-inflammatory effects of intravenous IgG^{4,5}. Conversely, the absence of terminal sialic acid residues increases the affinity to activating FcγR^{6,7}. The exact mechanism, by which these sugar moieties affect biological functions, is, however, not fully clarified⁸. Some^{9–11}, but not all¹², studies have suggested that anti-inflammatory effects of sialylated IgG are attributed to an enhanced binding of IgG to anti-inflammatory lectin receptors, such as the dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin⁹ or the dendritic cell immunoreceptor¹⁰ according to changes in the Fc conformation.

Bone homeostasis is assured by a concerted action of bone forming osteoblasts and bone resorbing osteoclasts. This balance can be impaired by the immune system as it is observed in bone destructive autoimmune diseases such as rheumatoid arthritis. However, while cytokine-mediated effects have been extensively studied in the past^{13,14}, there has been limited research regarding the impact of IgG or immune complexes on bone. Osteoclasts originate from the monocyte/macrophage lineage. Apart from specific growth factors and cytokines, such as the macrophage colony stimulating factor (M-CSF) and the receptor activator of NF-κB ligand (RANKL), osteoclastogenesis requires costimulatory signals from the immunoreceptor tyrosine-based activation motif-harboring proteins, FcR common γ chain (FcRγ) and DNAX-activating protein (DAP)12 (refs 15,16). In addition, osteoclasts express FcγR in comparable amounts to macrophages and dendritic cells^{17,18}, suggesting that they may be affected by immune complexes. This notion is supported by a study showing that crosslinking of FcγR on murine preosteoclasts leads to higher osteoclast numbers¹⁹ and our previous finding that antibodies against citrullinated proteins (ACPA) directly promote osteoclastogenesis²⁰. As pathogenic antibodies such as ACPA have been reported to contain less sialic acid in their Fc glycan than whole-blood IgG²¹, we further hypothesized that IgG sialylation may have an impact on immune complex–osteoclast interactions.

In this study, we used heat-aggregated IgG as an immune complex mimetic without antigen restrictions²² to investigate the effects of IgG sialylation on immune complex–osteoclast interactions. We found IgG sialylation to be a main regulator for the pro-osteoclastogenic potential of immune complexes as only non-sialylated immune complexes stimulated osteoclastogenesis *in vitro* as well as *in vivo*. In addition, we found higher Fc sialylation levels of both random IgG as well as specific autoantibodies to be correlated with higher bone volume in patients with RA. Administration of the sialic acid precursor ManNAc resulted not only in elevated sialylation levels of IgG, but also in a decreased susceptibility to collagen-induced arthritis (CIA)-mediated bone erosion in DBA/1J mice, suggesting a protective role of sialylated IgG against autoimmune-mediated bone loss.

Results

Desialylated immune complexes stimulate osteoclastogenesis.

To investigate the effects of immune complexes on human osteoclast formation, we differentiated human monocytes in the presence of M-CSF, RANKL and TGF-β to the stage of mono- and bi-nucleated preosteoclasts and challenged them with 100 μg ml^{−1} of immune complex mimetics derived by heat aggregation of pooled human IgG. One fraction of the IgG had been enzymatically desialylated before aggregation (Supplementary Fig. 2) to determine the importance of IgG sialylation for immune complex-mediated effects on preosteoclasts. In addition, we used immune complexes that had been deglycosylated, and therefore lost their FcγR binding capacity, as a control for unspecific effects by the amount of protein added to the osteoclast culture. After 24 h of stimulation, staining for tartrate-resistant acidic phosphatase (TRAP) was performed and osteoclasts were counted.

The stimulation with desialylated immune complexes (IC-ds) resulted in an accelerated osteoclastogenesis with an increase in osteoclast number, nuclei per osteoclast and bone resorption (Fig. 1). In contrast, after stimulation with untreated (sialylated) immune complexes (IC), we observed only a very weak tendency to higher osteoclast numbers and no difference in bone resorption. Neither the deglycosylated immune complexes (IC-dg) nor monomeric IgGs showed an effect, indicating a specific interaction between non-sialylated immune complexes and FcγR on preosteoclasts. This pro-osteoclastogenic effect of low-sialylated IgG complexes was confirmed with natural immune complexes consisting of low- or high-sialylated anti-TNP IgG and TNP-26-BSA (Supplementary Fig. 3).

Analyses by dynamic light scattering revealed similar particle sizes of native and desialylated aggregated IgG (Supplementary Fig. 4) excluding size differences as a reason for the strong osteoclastogenic effect observed with the desialylated immune complexes. In addition, all IgG samples had been verified to be free of endotoxin to avoid endotoxin-mediated side effects.

Immune complexes bind to FcγRII and III on preosteoclasts.

Next, we investigated how the distinct FcγR are regulated during the process of human osteoclastogenesis. Therefore, we isolated mRNA from osteoclast cultures every second day from the stage of monocytes (baseline, day 0) to the stage of mature osteoclasts (day 10). We observed an early upregulation of FcγRI and III as well as of the two immunoreceptor tyrosine-based activation motif-domain-harboring accessory proteins FcRγ and DAP12 (Fig. 2a). In contrast, the inhibitory FcγRIIB seemed to be mainly expressed by mature osteoclasts. The expression of FcγRIIA halved during the first 2 days of culture but remained stable for the rest of the culture period. To further test which FcγRs are expressed on the protein level at the preosteoclast stage (day 6–8), we performed immunofluorescence stainings on preosteoclasts. Confirming the mRNA data, all FcγRs could be detected (Fig. 2b), though we could not discriminate between FcγRIIA and FcγRIIB as the antibody against FcγRII recognizes both. Interestingly, smaller preosteoclasts exhibited the brightest expression signal, whereas larger, more mature cells that started to form podosomes seemed to have a less pronounced FcγR expression.

To determine which FcγR is responsible for the observed pro-osteoclastogenic effect of desialylated immune complexes, we added blocking antibodies against FcγRI, FcγRII and FcγRIII during the stimulation of preosteoclasts with desialylated immune complexes. Blocking of either FcγRII or FcγRIII resulted in a virtually complete abrogation of the pro-osteoclastogenic activity of desialylated immune complexes (Fig. 2c), indicating that a concerted interaction of those FcγRs is needed to provide the

Figure 1 | Fc-glycosylation determines the osteoclastogenic effects of human immune complexes. (a) Fold change of osteoclast number and (b) nuclei per osteoclast after 24 h treatment of human preosteoclasts with 100 $\mu\text{g ml}^{-1}$ of native, desialylated (ds) or deglycosylated (dg) monomeric (IgG) or complexed (IC) pooled human IgG. TRAP-positive cells with ≥ 3 nuclei were considered as osteoclasts. Bars show mean $\pm$ s.e.m. of five independent experiments. (c) Representative micro images. Scale bar, 100 μm . (d) Fold change of the resorbed area after 24 h treatment of human preosteoclasts with 100 $\mu\text{g ml}^{-1}$ of native or desialylated (ds) IgG complexes (IC) in calcium phosphate-coated wells. Bars show mean $\pm$ s.e.m. of five independent experiments (e) Representative micro images. Scale bar, 500 μm . Statistical analysis was performed with Mann-Whitney *U*-test. ***P* < 0.01.

signal for enhanced osteoclast development. In contrast, blocking of Fc γ RI had no effect, confirming previous reports about the dispensability of the high-affinity Fc γ R in osteoclast development and arthritis^{19,23}.

Desialylated immune complexes affect osteoclasts *in vivo*. We next wanted to investigate the implications of desialylated immune complexes on osteoclastogenesis *in vivo*. In patients with rheumatoid arthritis, immune complexes have been found in the synovial fluid of the joint space^{24–26}. To simulate this situation we decided to inject murine-aggregated IgG into the knee joints of C57BL/6 mice. Again, a part of the IgG had been enzymatically desialylated before heat aggregation. The control group was injected with PBS. The injections were repeated after 4 days. After additional 3 days, bones were dissected and analysed for the number and size of osteoclasts in the trabecular bone adjacent to the injection site.

Mice that were injected with 5 μg of desialylated immune complexes (IC-ds) displayed a significantly higher osteoclast number and surface compared with PBS-injected mice (Fig. 3a–c). The injection of 5 μg of untreated (sialylated) immune complexes (IC) resulted in a mild increase in osteoclast number and surface, but the effect was much less pronounced compared with desialylated immune complexes, confirming our *in vitro* data. Notably, this difference vanished after co-injection of 100 ng of TNF α . In this case, both aggregates were able to induce osteoclastogenesis already at an amount of 1 μg .

Haematoxylin-eosin staining revealed no differences in the degree of inflammation between the groups with only localized, if

any, inflammation around the small injury of the injection site (Fig. 3d,e). Hence, the observed pro-osteoclastogenic effect of desialylated immune complexes was independent of inflammatory tissue infiltration.

IgG glycosylation and bone loss in arthritis patients. To address to which degree IgG Fc sialylation affects human bone architecture, we measured the amount of Fc sialylation, galactosylation and fucosylation of total IgG and disease-specific autoantibodies (ACPA) in 30 patients with rheumatoid arthritis and related these results to bone microstructures of the distal radius measured by micro-computed tomography (μCT). We grouped the patients into tertiles with a low, medium or high degree of Fc sialylation, galactosylation and fucosylation of IgG, and compared bone volume, trabecular numbers and trabecular thickness between these groups.

In accordance with our previous experiments, patients exhibiting IgG with low-sialylated or low-galactosylated Fc portions displayed a significantly decreased bone volume compared with patients with high levels of IgG Fc sialylation or galactosylation (Fig. 4a,b,d). This effect seems mainly to be related to lower trabecular numbers, as no difference was observed in trabecular thickness. Similar results were obtained for disease-specific ACPA. The analysis of Fc fucosylation of IgG and ACPA did not show any relation to the bone structure (Fig. 4c). In addition, there was no difference between the groups regarding other parameters potentially impacting bone architecture or IgG glycosylation status²⁷, such as age, sex, disease duration, disease activity or treatment status (Supplementary Table 1), suggesting

Figure 2 | FcγRII and III mediate the signal of non-sialylated immune complexes on preosteoclasts. (a) Quantitative RT-PCR for relative mRNA levels of FcγR and adaptor proteins normalized on β2-microglobulin during osteoclastogenesis. Day 0 represents the stage of monocytes, day 6–8 the stage of late preosteoclasts and day 10 the stage of mature osteoclasts. Bars show mean ± s.e.m. of three independent experiments. (b) Fluorescence microscopy images of FcγR expression on human preosteoclasts. FcγR are depicted in green, phalloidin staining for actin is depicted in red and DRAQ5 staining for the nuclei is depicted in blue. Scale bar, 25 μm (representative images of three independent experiments). (c) Fold change of osteoclast number after stimulation of preosteoclasts with 100 μg ml⁻¹ of desialylated immune complexes (IC-ds) in the presence of 10 μg ml⁻¹ of blocking antibodies against indicated FcγR. TRAP-positive cells with ≥ 3 nuclei were considered as osteoclasts. Bars show mean ± s.e.m. of four independent experiments. Statistical analysis was performed with Mann–Whitney *U*-test. **P* < 0.05, ***P* < 0.01, ****P* < 0.001.

that the observed differences in bone structure were confined to IgG sialylation and galactosylation.

To further define the role of IgG sialylation in human bone structure, we addressed whether Fc sialylation influences the bone phenotype even before the clinical onset of disease. We thereby made use of the observation that autoantibodies emerge several years before the onset of rheumatoid arthritis and that in some individuals bone changes precede the clinical onset of the disease^{28,29}. When investigating IgG and ACPA Fc sialylation as well as bone structure in autoantibody-positive healthy individuals before the onset of rheumatoid arthritis, we again found that bone volume and trabecular numbers are significantly lower in individuals with low IgG and low ACPA sialylation compared with those with a high-sialylation status (Supplementary Fig. 5).

Sialylated ACPA lose their pro-osteoclastogenic activity. To determine whether the observed association between IgG Fc galactosylation and bone volume is due to a direct effect of IgG Fc galactosylation or simply the fact that galactose is needed for the attachment of sialic acid to the IgG glycan, we enzymatically galactosylated and sialylated two human monoclonal ACPA (clones 109 and C7) (Supplementary Fig. 6) that have been generated from B cells from the joints of

rheumatoid arthritis patients³⁰. In consistence with previously reported data²⁰, both clones promoted osteoclast differentiation (Fig. 4e). Sialylation of these antibodies resulted in a loss of their pro-osteoclastogenic activity to the point of even a slight inhibition of osteoclastogenesis. In contrast, galactosylation alone, without sialylation, did not seem to have an effect on the osteoclastogenic properties of the antibodies. In accordance with these findings, analysis of the sialic acid content per galactose residue on IgG in rheumatoid arthritis patients showed a significant association of higher sialylation rates with increased bone volume and trabecular numbers (Supplementary Fig. 7), suggesting that IgG galactosylation is of much less importance for osteoclastogenesis and bone loss than IgG sialylation.

***N*-acetylmannosamine treatment protects mice from CIA.** On the basis of these findings, we hypothesized that an increase of IgG sialylation protects from autoimmune-mediated bone loss. To test this hypothesis, we supplemented the drinking water of DBA/J1 mice exposed to CIA with the sialic acid precursor *N*-acetylmannosamine (ManNAc). ManNAc is rapidly metabolized into 5-*N*-acetylneuraminic acid, which is the most abundant mammalian sialic acid in the body³¹. Supplementation of ManNAc is effective in treating certain myopathies caused by

Figure 3 | Non-sialylated immune complexes stimulate osteoclastogenesis *in vivo*. (a) Number of osteoclasts per bone perimeter (N.Oc/B.Pm) and (b) osteoclast surface per bone surface (Oc.S/BS) in tibial bone of C57BL/6 mice with intra-articular injection of the indicated amounts of native or desialylated (ds) murine immune complexes. Mice were injected at day 0 and day 4 with bone dissection at day 7. When indicated, 100 ng of TNF α was added to the first injection. Bars show mean $\pm$ s.e.m. of ≥ 12 knee joints of three independent experiments. (c) Representative images of TRAP-stained tibial sections. Scale bar, 50 μ m. (d) Inflammation score of haematoxylin-eosin stained joint sections with a score of 0 representing a healthy joint and a score of 4 representing a completely destroyed joint. Bars show mean $\pm$ s.e.m. of ≥ 12 knee joints of three independent experiments. (e) Representative images of haematoxylin-eosin stained tibial sections. Scale bar, 500 μ m. Statistical analysis was performed with Mann-Whitney *U*-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

enzymatic defects associated with protein hyposialylation, which is currently evaluated in clinical studies³².

When using a similar protocol, mice fed with 10 g l⁻¹ ManNAc displayed a significantly higher IgG1 Fc sialylation compared with control mice that received either water or 10 g l⁻¹ mannose (Fig. 5a). There was also a slightly higher IgG1 Fc galactosylation in ManNAc-treated mice, but this was not significant. ManNAc treatment led to lower incidence, delayed onset and lower arthritis scores compared with controls challenged with either water or mannose (Fig. 5b–d). No significant difference in the amount of total IgG and collagen-specific antibodies between the groups was observed, suggesting that ManNAc treatment did not generally impair the IgG-based immune response (Fig. 5e). Furthermore, IgG Fc sialylation, but not galactosylation, was significantly higher in mice that developed no or mild arthritis than in mice that developed severe arthritis (Fig. 5f), suggesting that higher IgG Fc sialylation levels reduce the susceptibility to experimental arthritis.

Most importantly, ManNAc treatment was very effective to protect from local and systemic bone loss. μ CT measurements on the hind paws and the tibial bones revealed that ManNAc-treated mice did virtually not develop bone erosions and experienced less severe systemic bone loss during CIA compared with controls exposed to either water or mannose (Fig. 6a,b). Quantitative analysis showed that particularly trabecular bone loss was significantly less severe in mice treated with ManNAc than in controls (Fig. 6c). Moreover, protection from bone erosions in ManNAc-treated mice was accompanied by significant reduction in osteoclast numbers in the paws confirming the concept that higher IgG Fc sialylation impairs osteoclast differentiation and mitigates inflammatory bone loss (Fig. 6d,e). The protective effect of high-sialylated IgG against bone loss was further confirmed in an IgG transfer model, in which untreated or *in vitro* sialylated IgG from mice, previously immunized against methylated bovine serum albumin (mBSA), was transferred to naive mice (Supplementary Fig. 8). Challenge with mBSA into the knee

Figure 4 | Sialylation status of IgG and ACPA control bone mass in rheumatoid arthritis patients. (a–c) Bone morphometric parameters including bone volume per tissue volume (BV/TV), trabecular number (Tb.N) and trabecular thickness (Tb.Th) of RA patients with low, medium or high levels of Fc (a) sialylation, (b) galactosylation or (c) fucosylation of total IgG and ACPA. Bars show mean $\pm$ s.e.m. of 10 patients in each tertile. Cutoffs for tertiles are as follows: IgG Fc sialylation (low: $<14\%$, middle: $15\text{--}17.5\%$, high: $>17.5\%$), ACPA Fc sialylation ($<12\%$; $12\text{--}16\%$; $>16\%$), IgG Fc galactosylation ($<43.5\%$; $43.5\text{--}51\%$; $>51\%$), ACPA Fc galactosylation ($<44\%$; $44\text{--}54.5\%$; $>54.5\%$), IgG Fc fucosylation ($<85\%$; $85\text{--}87\%$; $>87\%$), ACPA Fc fucosylation ($<93\%$; $93\text{--}96\%$; $>96\%$). (d) Two-dimensional (upper panel) and 3-dimensional (lower panels) reconstruction of the bone architecture of patients with low and high degree of Fc sialylation; (e) Fold change of osteoclast number after treatment of preosteoclasts for 72 h with $10\text{ }\mu\text{g ml}^{-1}$ of native, galactosylated (gal) or galactosylated and sialylated (sial) monoclonal ACPA (clone 109 and C7). TRAP-positive cells with ≥ 3 nuclei were considered as osteoclasts. Bars show mean $\pm$ s.e.m. of three independent experiments. Statistical analysis was performed with Kruskal–Wallis test with Dunn's correction (a–c) and Mann–Whitney *U*-test (e). * $P < 0.5$, ** $P < 0.01$.

joint of the recipient mice led to increased osteoclast numbers only in mice that received untreated IgG. In contrast, mice receiving sialylated IgG were protected from enhancement of osteoclastogenesis, although they developed joint swelling to a similar extent as mice receiving untreated IgG.

Discussion

In the last years, there have been several studies with controversial findings regarding the effects of immune complexes on osteoclastogenesis^{17,19,33}. While the crosslinking of Fc γ R was found to be favourable for osteoclastogenesis¹⁹, it was unclear if the binding of immune complexes has the same effect. Here we show that the degree of IgG sialylation is of major importance for immune complex–osteoclast interactions and that only low- or non-sialylated immune complexes drive osteoclastogenesis *in vitro* as well as *in vivo*. Using random IgG, we further demonstrated that the pro-osteoclastogenic effect of non-sialylated immune complexes is not restricted to distinct antigen specificities but a common feature of all IgG antibodies.

In human serum only a minority of IgG of less than 20% is sialylated⁵. This low amount of sialylation suggests that the

observed difference in preosteoclast stimulation between sialylated and non-sialylated immune complexes is not merely due to a reduced binding of sialylated IgG to the classical Fc γ R, but more likely due to an active suppression by sialylated IgG for example by binding to C-type lectins, such as dendritic cell immunoreceptor and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin, which recognize sialylated IgG and are expressed on myeloid cells^{9,10}.

Interestingly, the putative suppressive function of sialylated IgG seems to be abrogated by strong pro-inflammatory stimuli, as, in our mouse model, after co-injection of 100 ng of TNF- α also the sialylated immune complexes promoted osteoclastogenesis.

When investigating the IgG Fc glycans of rheumatoid arthritis patients, we found a significant correlation between the Fc sialylation levels of random IgG as well as disease-specific autoantibodies (ACPA) and bone architecture. Patients with low levels of IgG Fc sialylation displayed lower bone volumes and lower trabecular numbers, while other parameters, such as age, sex or disease duration, did not differ among the groups. ACPA are well established as a major risk factor for the development of rheumatoid arthritis and are associated with a stronger disease course and enhanced bone erosion^{34,35}. Of note, ACPA have been

Figure 5 | Treatment with ManNAc increases sialylation of IgG1 and reduces susceptibility to CIA. (a) Quantification of total serum IgG1 Fc sialylation and galactosylation at day 32 in non-induced control mice and mice induced for CIA receiving treatment with water, 10 g l^{-1} mannose or 10 g l^{-1} ManNAc. (b) Incidence of CIA. (c) Arthritis scores. (d) Representative images of hind paws at day 32. Scale bar, 5 mm. (e) Quantification of total serum IgG and collagen-specific IgG at day 32. Bars show mean $\pm$ s.e.m. of combined data from two independent experiments (non-induced control group: $n = 9$ mice; all other groups: $n = 13$ mice). (f) Quantification of total serum IgG1 Fc sialylation and galactosylation at day 32 from mice that stayed healthy or developed mild arthritis (score 0–4) and from mice that developed severe arthritis (score > 4). Bars show mean $\pm$ s.e.m. of combined data from all mice subjected to CIA (score 0–4: $n = 13$; score > 4 : $n = 25$). Statistical analysis was performed with Mann-Whitney U -test. * $P < 0.5$, ** $P < 0.01$.

reported to be less sialylated than random IgG²¹, which may explain their strong pathogenicity. We now provided evidence that this feature may also be a reason for the direct pro-osteoclastogenic effect of ACPA that has been published earlier²⁰. Indeed, ACPA that were sialylated *in vitro* completely lost their capacity to drive osteoclastogenesis.

We have also found a significant correlation between IgG Fc galactosylation and bone architecture in rheumatoid arthritis patients. But, as *in vitro* galactosylation of ACPA did not alter their pro-osteoclastogenic activity, IgG galactosylation does not seem to play a major role for direct immune complex–preosteoclast interactions. However, we cannot exclude indirect effects of IgG galactosylation on osteoclastogenesis for example by influencing the overall joint inflammation.

On the basis of our data we hypothesized that an enhancement of IgG sialylation may be a treatment strategy to inhibit autoimmune-mediated bone loss. To test this hypothesis, we used the sialic acid precursor ManNAc, which is an interesting approach as it can be taken up orally, has been shown to affect myopathies related to hyposialylation³² and enhances overall protein sialylation³⁶. Indeed, mice induced for CIA that were fed with ManNAc displayed a significant increase in IgG sialylation compared with mice that received water or a mannose solution. Treatment with ManNAc not only resulted in a mitigated course of arthritis, but also blocked inflammatory

osteoclastogenesis and bone erosion. Whether such an approach is effective in the treatment of rheumatoid arthritis and emerges as a more feasible treatment approach than costly intravenous immunoglobulin infusions, which have shown efficacy in the treatment of rheumatoid arthritis^{37,38}, however, remains to be determined.

In summary, our data show that, apart from the regulation of immune effector functions, IgG sialylation controls osteoclast differentiation and bone mass in mice and humans pointing to a new link between the adaptive immune system and bone with direct relevancy for human disease.

Methods

Desialylation and deglycosylation of IgG and IC generation. Human IgG was taken from Beriglobin (Behring). Murine IgG was obtained from pooled serum of healthy C57BL/6 mice (Charles River) of different age and sex by purification over a protein G column (GE Healthcare) according to the manufacturer's instructions. For desialylation, 1 mg of human or murine IgG was incubated with 5U or 10,000U neuraminidase (NEB) for 24 h or 48 h, respectively, at 37 °C. For deglycosylation, human IgG was incubated with 500 U mg^{−1} PNGase F (NEB) for 24 h at 37 °C. The efficiency of the enzymatic digestion was tested with a lectin blot. The digested IgG was purified over a protein G column (GE Healthcare) according to the manufacturer's instructions and tested for endotoxin contamination using a LAL chromogenic endotoxin quantitation kit (Thermo scientific). Protein concentration was determined with the DC protein assay (Bio-Rad) and adjusted to 10 mg ml^{-1} . Immune complexes were obtained by heat aggregation of the IgG at 63 °C for 30 min.

Figure 6 | Treatment with *N*-acetylmannosamine (ManNAc) inhibits arthritis-mediated bone loss. (a,b) Representative 3-dimensional reconstructions of the bone architecture of hind paws (a) and tibial bones (b) of non-induced control mice and mice induced for collagen-induced arthritis (CIA) treated with water, 10 g l^{-1} mannose or 10 g l^{-1} ManNAc. (c) Bone morphometric parameters of the tibiae including trabecular and cortical bone volume per tissue volume (tBV/TV; cBV/TV) and trabecular and cortical bone mineral density (tBMD; cBMD). Bars show mean $\pm$ s.e.m. from one representative experiment (non-induced control group: $n=5$ mice; water treated group: $n=7$ mice; all other groups $n=6$ mice). (d) Representative images of TRAP-stained paw sections. Scale bar, $200 \mu\text{m}$. (e) Histological parameters of the hind paws including eroded area per tissue area (E.Ar/T.Ar) and osteoclast number per tissue area (N.Oc/T.Ar). Bars show mean $\pm$ s.e.m. of combined data from two independent experiments (non-induced control group: $n=9$ mice; all other groups: $n=13$ mice). Statistical analysis was performed with Mann-Whitney *U*-test. $**P<0.01$.

Galactosylation and Sialylation of monoclonal antibodies. Monoclonal ACPA from the clones 109 and C7 and anti-TNP antibodies were generated as described elsewhere^{30,39}. For galactosylation, 1 mg of IgG was incubated with 10 μ M UDP-galactose (Calbiochem) and 2.5 mU of β 1-4 galactosyltransferase (Sigma) in 50 mM MOPS, pH 7.2 with 20 mM $MnCl_2$ for 48 h at 37 °C. For sialylation, 1 mg of IgG was incubated with 10 μ M CMP-sialic acid (Calbiochem) and 10 mU of α 2-6 sialyltransferase (Sigma) in 50 mM MES, pH 6.0 with 10 mM $MnCl_2$ for 48 h at 37 °C. The reactions were confirmed with a lectin blot.

Lectin blotting. IgG was resolved on a sodium dodecyl sulfate–PAGE (SDS–PAGE) gel under reducing conditions, transferred to PVDF membranes and blocked with 3% deglycosylated gelatine (Sigma). Blots were incubated with biotinylated *Sumbucus nigra* lectin (2 μ g ml^{-1}) for sialic acid, *Erythrina cristagalli* lectin (5 μ g ml^{-1}) for galactose or *lens culinaris* agglutinin (5 μ g ml^{-1} , all vector laboratories) for the detection of the core glycan, followed by incubation with an alkaline phosphatase conjugated mouse-anti-biotin antibody (Sigma) and detection with 4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate (Roche).

Dynamic light scattering measurements. Angular-dependent dynamic light scattering was performed using a 6,328 nm-Laser and a CGS3-Goniometer (ALV) at a temperature of 20 °C with two avalanche diode detectors and an ALV-5000 correlator with 320 channels under cross-correlation. A range of scattering angles of $30^\circ < \theta < 150^\circ$ was covered in 10° steps. Intensity autocorrelation functions were transferred into electric field autocorrelation functions via Siegert relation and then transformed into the distribution of relaxation times $A(\tau)$ via regularized Laplace transformation. Resulting mean relaxation times for each angle were transferred into the apparent diffusion coefficient D_{app} , which was then extrapolated to zero scattering angle (scattering vector square); the extrapolated result subsequently gave the hydrodynamic radius R_H through Stokes–Einstein relationship.

Generation and stimulation of preosteoclasts. Human monocytes were purified by plastic adhesion of peripheral blood mononuclear cells that had been isolated from EDTA-blood of normal healthy donors using a Ficoll gradient (Lymphoflo, BioRad). Preosteoclasts were generated in α -Mem (Invitrogen) containing 10% fetal bovine serum (Biocrome) and 1% penicillin/streptomycin (Invitrogen) with 30 ng ml^{-1} M-CSF, 10 ng ml^{-1} RANKL and 1 ng ml^{-1} TGF- β (all Peprotech). After 6–9 days (depending on the donor), first binucleated cells appeared and preosteoclasts were incubated as indicated with the different IgG preparations. Osteoclast differentiation was evaluated by staining for TRAP using a Leukocyte Acid Phosphatase Kit (Sigma) according to the manufacturer's instructions.

For the resorption assay, human preosteoclasts were generated and stimulated with IgG complexes on plates coated with calcium phosphate (Corning) under the same conditions as described above. Resorption was visualized with a von Kossa staining. In brief, we lysed the cells with water and incubated the wells for 30 min with 5% silver nitrate. After extensive washing, the silver stain was developed for 1 min with 5% sodium carbonate in 25% formaldehyde and unreacted silver was removed with 5% sodium thiosulfate for 5 min. For evaluation, photos were taken and the percentage of the resorbed area was calculated with Adobe Photoshop CS5 extended.

Blocking of Fc γ receptors. Preosteoclasts were generated as described above and incubated for 1 h with 10 μ g ml^{-1} of blocking antibodies against Fc γ RI (10.1, biolegend), Fc γ RII (AT10, abcam), Fc γ RIII (3G8, provided from the group of Falk Nimmerjahn) or isotype control (mouse IgG1, κ , biolegend), respectively. Subsequently, 100 μ g ml^{-1} of desialylated aggregated IgG was added for 6 h, followed by a complete medium exchange. After additional 18 h, osteoclast differentiation was evaluated by staining cells for TRAP using a Leukocyte Acid Phosphatase Kit (Sigma) according to the manufacturer's instructions.

Immunofluorescence staining. Preosteoclasts were fixed with 4% PFA (pH 7.2) in PBS for 10 min at 37 °C. Fixed samples were then permeabilized and blocked for 1 h with 3% BSA in 0.1% Triton X-100 in PBS (all Sigma). Next, samples were incubated for 90 min with primary antibodies against Fc γ RI (12.7 μ g ml^{-1} , 10.1, Abcam), Fc γ RII (1:200, Abcam), Fc γ RIII (2 μ g ml^{-1} , J5511, Abcam) followed by 1 h incubation with the alexa-fluor-488 conjugated secondary antibodies (goat-anti-mouse for Fc γ RI and III and goat-anti-rabbit for Fc γ RII, 10 μ g ml^{-1}) together with alexa-fluor-568-labelled phalloidin (1:200). Samples were then incubated with DRAQ5 (all Life technologies) and mounted with FluorSave reagent (Calbiochem). Fluorescence images were acquired with a Zeiss confocal microscope.

RNA isolation and quantitative RT-PCR analysis. Osteoclasts were differentiated from human monocytes as described above. Directly after monocyte isolation or after various times of culture, total RNA was extracted with peqGOLD TriFast (Peqlab) according to the manufacturer's instructions. RNA was transcribed into cDNA using oligo(dT) primers and MuLV reverse transcriptase (Roche). Quantitative real-time PCR was performed with SYBR Green I-dTTP (Eurogentec) and

the following primer pairs: β 2-microglobulin (β 2-MG) forward 5'-GATGAGTAT GCCTGCCGTGTG-3' and β 2-MG reverse 5'-CAATCCAAATGCGGCATCT-3', *fcyrl* forward 5'-GTGTCATGCGTGAAGGATA-3' and *fcyrl* reverse 5'-GCAC TGGAGCTGGAAATAGC-3', *fcyrl2a* forward 5'-CCAGCATGGGACGCTTTC ACC-3' and *fcyrl2a* reverse 5'-TGGGCAGCCTTCACAGGATCA-3', *fcyrl2b* forward 5'-GCGGCGATTGTTGCTGCTGTA-3' and *fcyrl2b* reverse 5'-AGAGCATCC GGGTGCATGAGA-3', *fcyrl3* forward 5'-ACAGGTGCCAGCAACCTC-3' *fcyrl3* reverse 5'-TTCCAGCTGTGACACCTCAG-3', *fcyrl* forward 5'-TGATTCCAG-CAGTGGTCTTGCTCT-3' and *fcyrl* reverse 5'-ATGCAGGCATATGTGATGC CAACC-3', *dap12* forward 5'-CAGCGACCCGAAACAGCGT-3' and *dap12* reverse 5'-CGGCCCTCTGTGTGTTGAGGTGC-3'.

Intraarticular injection of immune complexes. All animal experiments were approved by the government of Mittelfranken, Germany. Male 8-week-old C57BL/6-mice (Charles River) were randomly allocated into groups and administered with an intraarticular injection through the patellar tendon of 5 μ l of PBS containing the indicated amounts of murine immune complexes. The injection was repeated after 4 days. After additional 3 days, mice were killed and the bones were dissected for histological analysis.

Induction of CIA and treatment with N-acetylmannosamine. Chicken collagen type II (4 mg ml^{-1} ; Sigma) was emulsified in equal amounts with complete Freund's adjuvant (Sigma) containing 5 mg ml^{-1} heat-inactivated *Mycobacterium tuberculosis* (H37Ra; Difco). For the induction of CIA, male 7-week-old DBA/1J mice (Janvier) were injected s.c. at the base of the tail with 100 μ l of this emulsion. Mice were rechallenged after 21 days. N-acetylmannosamine was constantly administered to the drinking water at a concentration of 10 g l^{-1} , beginning with the primary immunization. Control mice received water or water containing 10 g l^{-1} mannose (all Sigma). The allocation of the mice into the different groups was performed randomly. Clinical arthritis was evaluated every second day using a scoring system from 0 (no swelling) to 3 (severe swelling and erythema) for every limb, resulting in a maximally possible score of 12 per animal.

Antigen-induced arthritis transfer model. mBSA (2 mg ml^{-1} ; Sigma) was emulsified in equal amounts with complete Freund's adjuvant (Sigma) containing 5 mg ml^{-1} heat-inactivated *Mycobacterium tuberculosis* (H37Ra; Difco). Male 6-week-old Balb/c mice (Janvier) were injected s.c. with 100 μ l of this emulsion and simultaneously injected i.p. with 5×10^8 heat-inactivated *Bordetella pertussis* (National Institute for Biological Standards and Control (NIBSC)) at day 0 and 7. After 21 days, the mice were challenged with 100 μ g mBSA into one knee joint. At day 28, blood was taken and IgG was isolated with a protein G column (GE Healthcare) according to the manufacturer's instructions. For sialylation, 1 mg of IgG was incubated with 750 μ M CMP-sialic acid (Calbiochem) and 30 mU of α 2-6 sialyltransferase (Sigma) in 100 mM Tris/HCl, pH 8.0 with 1 mM $MnCl_2$ for 4 days at 37 °C. The reaction was confirmed with a lectin blot. For the IgG transfer, 2 mg of untreated or sialylated AIA-IgG was injected i.v. into naive male 9-week-old Balb/c (Janvier) mice. After 1 and 5 days, the right knee joints were injected with 100 μ g mBSA. The left knee joints served as internal controls. Knee joint swelling was determined using a dial thickness gauge (Peacock) and expressed relative to the knee diameter at day 0. At day 8, mice were killed and the bones were dissected for histological analysis.

Measurement of IgG concentrations in mouse serum. The serum concentrations of IgG were measured with an enzyme-linked immunosorbent assay (ELISA) quantitation kit (Bethyl Laboratories). For the assessment of collagen-specific IgG, plates were coated with 10 μ g ml^{-1} chicken collagen type II (Sigma) instead of the capture antibody.

Histology. Bones were fixed for 6 h in 4% formalin and decalcified in EDTA (Sigma-Aldrich). Serial paraffin sections (2 μ m) were stained for TRAP using a Leukocyte Acid Phosphatase Kit (Sigma) according to the manufacturer's instructions or with haematoxylin-eosin. All analyses were performed using a microscope (Nikon) equipped with a digital camera and an image analysis system for performing histomorphometry (Osteomeasure; Osteometrics).

Micro-computed tomography of mice. μ CT analyses were performed with a SCANCO Medical μ CT 40 scanner using the following parameters: voltage, 40 kV; X-ray current, 250 μ A; exposure time, 5,000 ms/projection for 720 projections; matrix, $1,024 \times 1,024$; voxel size in reconstructed image, 9 μ m. Images were analysed with SCANCO evaluation software for parameters at the metaphyses of the proximal tibiae: ratio of bone volume to total volume, trabecular number and trabecular thickness.

Patients. Thirty rheumatoid arthritis patients were analysed in detail for (i) bone structure by micro-computed tomography, (ii) IgG and ACPA glycosylation status and (iii) their demographic and disease-specific characteristics. The methodology of bone structure and antibody glycosylation analysis is described below. Age and

sex were collected as the main demographic parameters showing a standard population of rheumatoid arthritis patients with a mean ($\pm$ s.e.m.) age of 52.8 ± 2.8 years and a dominance of female patients (20 out of 30). As disease-specific parameters we analysed disease duration, disease activity and anti-rheumatic treatment (conventional versus biological disease modifying anti-rheumatic drug therapy (DMARD)) in all the patients. Patients had established rheumatoid arthritis with a mean disease duration of 4.6 ± 0.9 years. Their disease activity was 3.5 ± 0.2 units according to the disease activity score (DAS) 28, resembling moderate disease activity. Furthermore, both, patients with conventional DMARD (methotrexate) therapy (16 out of 30) and biological DMARD (tumour necrosis factor inhibitor) therapy (14 out of 30) were analysed. In addition to the 30 patients with rheumatoid arthritis, a small group of 12 healthy individuals with autoantibody positivity, but no arthritis, was analysed for bone architecture and antibody glycosylation status as well as to exclude potential effects related to inflammation. All analyses of human material were performed in full agreement with institutional guidelines and with the approval of the Ethical committee of the University Hospital Erlangen (permit # 248_13B). Informed consent and permission to use the obtained data for research were obtained from all subjects enrolled in the study.

Micro-computed tomography in patients. HR-pQCT measurements were performed by an XtremeCT scanner (Scanco, Switzerland) at the ultra-distal radius of the right arm using the manufacturer's standard *in vivo* protocol. The reference line was set manually. The first CT-slice was 9.5 mm proximal to the reference line. For scanning, the hand was immobilized in a carbon fibre cast. An antero-posterior scout view was then used to determine the region of interest. A total of 111 slices (voxel size $82 \mu\text{m}$) were carried out. Details of the HR-pQCT measurements of the distal radius have been previously described by Boutroy *et al.*⁴⁰ All measurements were performed with the same software (Version 6.0) by two well-trained physicians. Daily cross-calibrations with standardized control phantoms (Moehrendorf, Germany) were conducted to standardize measurements. Bone microstructure including trabecular bone volume fraction (BV/TV), trabecular number (Tb.N, 1/mm) and trabecular thickness (Tb.Th, mm) were analysed.

IgG isolation. Human ACPA-IgG and ACPA-depleted IgG were purified from 30 μl of serum. ACPA were isolated by antigen affinity chromatography using cyclic citrullinated peptide (CCP2)-coated beads prepared by mixing biotinylated CCP2 dissolved in PBS at 1 mg ml^{-1} with Neutravidin Plus UltraLink resin (Pierce, Thermo Scientific) for 1 h at room temperature (RT). Following extensive washing, the CCP2 beads were dissolved in PBS and loaded into an Of1100 96-well filter plate (Orochem). Prediluted serum samples were applied and binding of ACPA to the beads was allowed by shaking the plate at 600 r.p.m. for 2 h at RT. Following incubation, the plate was centrifuged for 2 min at $1,500 \times g$ and the flow through was collected in a 96-deepwell storage plate (Thermo). Beads were washed with 200 μl PBS and 25 mM ammonium bicarbonate followed by ACPA elution using 100 mM formic acid at pH 2.5 (pro analysis for mass spectrometry; Merck). The elution fraction was directly neutralized with 2 M TRIS. IgG (flow-through) and eluted ACPA-IgG were further purified using CaptureSelect IgG-Fc (Hu) Affinity Matrix (life technologies). To this end, 20 μl of CaptureSelect affinity resin was loaded into a 96-well filter plate (Of1100, 0.7 ml per well, PE frit, Orochem) and washed three times with 200 μl PBS using a vacuum manifold (Millipore), before transferring the CCP2 flow-through/elution samples to the plate. The plate was then incubated on a multiwell plate shaker (1.5 mm orbit, VWR) for 1 h at 450 r.p.m. to facilitate the binding of antibodies to the beads. The latter were then washed three times with 200 μl PBS using vacuum before the elution of (ACPA)-IgG by adding 100 μl of 100 mM formic acid at pH 2.4 (pro analysis for mass spectrometry; Merck). Again, the plate was shaken for 5 min on a shaking platform at 450 r.p.m. and elution of the antibodies was performed by centrifuging 1 min at $500 \times g$. IgG of DBA/1J mice were isolated from 2 μl of serum (pre-diluted in 200 μl PBS) using 20 μl of Protein G-Sepharose Fast Flow resin (GE Healthcare) according to the protocol described above for IgG capturing using CaptureSelect IgG-Fc (Hu) Affinity Matrix.

Fc-glycosylation analysis by nano-LC-ESI-MS. IgG and ACPA-IgG eluates were dried in a vacuum centrifuge and subjected to tryptic digest by adding 200 ng trypsin (sequencing grade, Promega) in 40 μl ammonium bicarbonate buffer followed by overnight incubation at 37°C . Digested ACPA and IgG antibodies were separated and analysed on an Ultimate 3000 UPLC system (Dionex Corporation, USA) coupled to a quadrupole-TOF mass spectrometer (MS) (micrOTOF-Q or nanoXis ultra-high resolution QTOF; Bruker Daltonics)⁴¹. The samples were injected and concentrated on a C18 solid phase extraction trap column (Dionex Acclaim PepMap100, 5 mm $\times$ 300 μm i.d.) conditioned with 0.1% TFA (mobile phase A) for 1 min at $25 \mu\text{l min}^{-1}$. Sample separation was achieved on an Ascentis Express C18 nano-liquid chromatography column (50 mm $\times$ 75 μm i.d., 2.7 μm HALO fused core particles, Supelco) conditioned at 900 nl min^{-1} with mobile phase A after which the following gradients of mobile phase A and 95% acetonitrile (mobile phase B) were applied: 0 min 3% B, 2 min 6% B, 4.5 min 18% B, 5 min 30% B, 7 min 30% B, 8 min 1% B and 11 min 1% B for human IgG; 0 min 3% B, 2 min 6% B, 4.5 min 18% B, 6 min 30% B, 8 min 30% B, 9 min 1% B and 12 min 1% B for mouse IgG. The UPLC was interfaced to the MS with a standard ESI source (Bruker

Daltonics) and a sheath-flow ESI sprayer (capillary electrophoresis ESI-MS sprayer; Agilent Technologies)⁴¹. Mass spectra were recorded from m/z 600 to 2,000 with two averages at a frequency of 0.5 Hz. To reduce glycan decay during ion transfer, the quadrupole ion energy and collision energy of the MS were set at 2 and 4 eV, respectively. The total analysis time per sample was 13 and 14 min for human and mouse IgG samples, respectively. IgG Fc-glycopeptides were identified based on their retention times and their accurate monoisotopic masses of double protonated and triple-protonated charged ions (human IgG1: EEQYN*STYR, mouse IgG1: EEQFN*STFR and mouse IgG2A: EDYN*STLR; N* stands for an N-glycosylated asparagine). Internal calibration of LC-MS spectra was performed in Bruker DataAnalysis 4.0 using a list of known glycopeptides, before exportation of the data to the mzXML format. A list of glycopeptide features, defined as a retention time window of ± 15 –20 s and a peak maximum within mass window of $\pm m/z$ 0.07, was extracted from each data set using the in-house developed 'Xtractor2D or 3D' software⁴¹. The extracted data, merged on a sample-data matrix, were finally evaluated using Microsoft Excel. Quality of mass spectra was determined based on intensities of total IgG1 glycoforms in both human and mice samples. The level of galactosylation, sialylation and fucosylation of human IgG1 were calculated using the following formulas: galactosylation = $(G1F + G1FN + G1FS + G1FNS + G1 + G1N + G1S) \times 0.5 + G2F + G2FN + G2FS + G2FNS + G2 + G2N + G2S$; fucosylation = $G0F + G1F + G2F + G0FN + G1FN + G2FN + G1FS + G2FS$; sialylation = $G1FS + G2FS + G1FNS + G2FNS + G1S + G2S$ (G: galactose, F: Fucose; N: bisecting N-Acetylglucosamine; S: sialic acid). The degree of galactosylation and sialylation of mouse IgG1 and IgG2a was calculated using the following formulae: galactosylation = $(G1 + G1F + G1FN + G1FNeuAc + G1FNeuGc) \times 0.5 + (G2F + G3F + G2FNeuGc + G3FNeuGc + G2FNeuGc2) \times 1$; sialylation = $(G1FNeuAc + G1FNeuGc + G2FNeuGc + G3FNeuGc) \times 0.5 + G2FNeuGc2$. (G: galactose, F: Fucose; N: bisecting N-Acetylglucosamine; NeuAc: N-Acetylneuraminic Acid; NeuGc: N-Glycolylneuraminic Acid).

Data procession and statistical analysis. We performed computations and charts with GraphPad Prism 5.03 software. If not indicated differently, two-sided Mann–Whitney *U* test was used for statistical analysis ($*P < 0.05$; $**P < 0.01$; $***P < 0.001$). For comparison of glycosylation tertiles with respect to bone data in humans, the Kruskal–Wallis test with Dunn's correction was used. We also performed a *post-hoc* power calculation for bone data in humans by taking into account the size of the observed effect and a type I error probability of 2.5% (adjusted for two tests, that is, low versus medium, low versus high), resulting in a power of 77.2% for the corresponding significant finding. Data are presented as mean $\pm$ s.e.m. as well as medians and inter-quartile ranges. All analysis was performed in a blinded manner.

References

- Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. *Annu. Rev. Immunol.* **25**, 21–50 (2007).
- Anthony, R. M. & Nimmerjahn, F. The role of differential IgG glycosylation in the interaction of antibodies with Fcγ receptors in vivo. *Curr. Opin. Organ Transplant.* **16**, 7–14 (2011).
- Yamaguchi, Y. *et al.* Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. *Biochim. Biophys. Acta.* **1760**, 693–700 (2006).
- Anthony, R. M. *et al.* Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. *Science* **320**, 373–376 (2008).
- Bohm, S., Schwab, I., Lux, A. & Nimmerjahn, F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. *Semin. Immunopathol.* **34**, 443–453 (2012).
- Scallan, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N. & Raju, T. S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. *Mol. Immunol.* **44**, 1524–1534 (2007).
- Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. *Science* **313**, 670–673 (2006).
- Campbell, I. K. *et al.* Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. *J. Immunol.* **192**, 5031–5038 (2014).
- Anthony, R. M., Wermeling, F., Karlsson, M. C. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIG. *Proc. Natl Acad. Sci. USA* **105**, 19571–19578 (2008).
- Massoud, A. H. *et al.* Dendritic cell immunoreceptor: A novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. *J. Allergy Clin. Immunol.* **133**, 853–863 e855 (2014).
- Sondermann, P., Pincetic, A., Maamary, J., Lammens, K. & Ravetch, J. V. General mechanism for modulating immunoglobulin effector function. *Proc. Natl Acad. Sci. USA* **110**, 9868–9872 (2013).
- Yu, X., Vasiljevic, S., Mitchell, D. A., Crispin, M. & Scanlan, C. N. Dissecting the molecular mechanism of IVIG therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. *J. Mol. Biol.* **425**, 1253–1258 (2013).

13. Braun, T. & Zwerina, J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. *Arthritis Res. Ther.* **13**, 235 (2011).
14. Zhao, B. & Ivashkiv, L. B. Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. *Arthritis Res. Ther.* **13**, 234 (2011).
15. Koga, T. *et al.* Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. *Nature* **428**, 758–763 (2004).
16. Hayashi, M. *et al.* Osteoprotection by semaphorin 3A. *Nature* **485**, 69–74 (2012).
17. Grevers, L. C. *et al.* Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells. *Ann. Rheum. Dis.* **72**, 278–285 (2013).
18. Harre, U. *et al.* Moonlighting osteoclasts as undertakers of apoptotic cells. *Autoimmunity* **45**, 612–619 (2012).
19. Seeling, M. *et al.* Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. *Proc. Natl Acad. Sci. USA* **110**, 10729–10734 (2013).
20. Harre, U. *et al.* Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. *J. Clin. Invest.* **122**, 1791–1802 (2012).
21. Scherer, H. U. *et al.* Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. *Arthritis Rheum.* **62**, 1620–1629 (2010).
22. Henson, P. M. & Spiegelberg, H. L. Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses. *J. Clin. Invest.* **52**, 1282–1288 (1973).
23. Ji, H. *et al.* Arthritis critically dependent on innate immune system players. *Immunity* **16**, 157–168 (2002).
24. Zhao, X. *et al.* Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. *Arthritis Res. Ther.* **10**, R94 (2008).
25. Van Steendam, K. *et al.* Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. *Arthritis Res. Ther.* **12**, R132 (2010).
26. Mathsson, L., Lampa, J., Mullazehi, M. & Ronnelid, J. Immune complexes from rheumatoid arthritis synovial fluid induce FcγRIIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-α by peripheral blood mononuclear cells. *Arthritis Res. Ther.* **8**, R64 (2006).
27. Collins, E. S. *et al.* Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. *Rheumatology* **52**, 1572–1582 (2013).
28. Rantapää-Dahlqvist, S. *et al.* Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. *Arthritis Rheum.* **48**, 2741–2749 (2003).
29. Kleyer, A. *et al.* Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. *Ann. Rheum. Dis.* **73**, 854–860 (2014).
30. Amara, K. *et al.* Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. *J. Exp. Med.* **210**, 445–455 (2013).
31. Keppler, O. T. *et al.* UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. *Science* **284**, 1372–1376 (1999).
32. Galeano, B. *et al.* Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. *J. Clin. Invest.* **117**, 1585–1594 (2007).
33. MacLellan, L. M. *et al.* Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. *Arthritis Rheum.* **63**, 3897–3907 (2011).
34. van Gaalen, F. A. *et al.* Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. *Arthritis Rheum.* **50**, 709–715 (2004).
35. Saeki, Y. *et al.* Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA). *Rheumatol. Int.* **33**, 451–456 (2013).
36. Gagiannis, D., Gossrau, R., Reutter, W., Zimmermann-Kordmann, M. & Horstkorte, R. Engineering the sialic acid in organs of mice using N-propanoylmannosamine. *Biochim. Biophys. Acta* **1770**, 297–306 (2007).
37. Tumiati, B., Casoli, P., Veneziani, M. & Rinaldi, G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. *Arthritis Rheum.* **35**, 1126–1133 (1992).
38. Muscat, C. *et al.* Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. *Ann. Rheum. Dis.* **54**, 382–385 (1995).
39. Lux, A., Yu, X., Scanlan, C. N. & Nimmerjahn, F. Impact of immune complex size and glycosylation on IgG binding to human Fcγ receptors. *J. Immunol.* **190**, 4315–4323 (2013).
40. Boutroy, S., Bouxsein, M. L., Munoz, F. & Delmas, P. D. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. *J. Clin. Endocrinol. Metab.* **90**, 6508–6515 (2005).
41. Selman, M. H. *et al.* Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. *J. Proteomics* **75**, 1318–1329 (2012).

Acknowledgements

We thank Barbara Happich, Isabell Schmidt, Hedwig Symowski, Maurice H.J. Selman and Lise Hafkenschied for technical assistance. We also want to thank Pierre Jurdic and his team for advice and technical assistance with microscopy. This study was supported by the Deutsche Forschungsgemeinschaft (Focus program SPP1468 IMMUNOBONE), the Bundesministerium für Bildung und Forschung (BMBF; METARTHROS), the Marie-Curie project Osteoimmune, the TEAM and Masterswitch project of the European Union, the IMI funded project BTCure, and the Interdisciplinary Centre for Clinical Research of the University of Erlangen-Nuremberg. U.H. was supported by the doctoral training program GK1660 from the Deutsche Forschungsgemeinschaft. R.E.M.T. was supported by the Dutch Arthritis Foundation. H.U.S. is a recipient of a Clinical fellowship of The Netherlands Organization for Health Research and Development.

Author contributions

U.H., M.H. and G.S. designed and performed experiments and analysed data. U.H., S.C.L., W.B. and K.D. performed animal experiments. R.P. and A.L. contributed to the enzymatic modification of IgG. S.F. and F.G. performed and analysed the dynamic light scattering measurements. K.A., V.M. and L.K. generated and provided monoclonal ACPA. Y.R., C.A.K., R.E.M.T. and H.U.S. isolated and analysed IgG from sera. H.B., G.K., F.N. and M.H. provided valuable material and intellectual input. U.H. and G.S. wrote the manuscript.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: There are no competing financial interests.

Reprints and permission information is available online at <http://npj.nature.com/reprintsandpermissions/>

How to cite this article: Harre, U. *et al.* Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. *Nat. Commun.* **6**:6651 doi: 10.1038/ncomms7651 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>